Syschem Share Price

Syschem (India) Limited, with its corporate operations in Chandigarh, functions as a pharmaceutical active pharmaceutical ingredient (API) and specialty chemicals manufacturing company in India. The company was incorporated in 1993 and is headquartered in Punjab. Syschem (India) is engaged in the production and sale of active pharmaceutical ingredients (APIs), intermediates, bulk drugs, and specialty chemicals. The company’s APIs and intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, and cefadroxil. The company also engages in the distillation of specialty solvents such as methonel, acetonitrile, ethyl acetate, and THF, as well as contract manufacturing business. 

Syschem share price on BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical API and bulk drug sector. The company’s financial health depends on API production volumes, raw material costs including chemical intermediates, capacity utilization rates, export demand, and the performance of its antibiotic API and specialty solvent segments. Syschem stock price is influenced by various factors such as earnings, regulatory changes from the Central Drugs Standard Control Organization, drug price controls, and global demand for penicillin-based antibiotics. In the longer run, strategies such as expansion into new API categories, capacity expansion at new production units, and contract manufacturing development affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Syschem live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Syschem live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Syschem stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Syschem (India) Limited Company Fundamentals 

A. Company Background

Syschem (India) Limited was incorporated in 1993 and is engaged in the production and sale of active pharmaceutical ingredients (APIs), intermediates, bulk drugs, and specialty chemicals in India. The company operates primarily in the pharmaceutical manufacturing segment, supplying products such as amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, and cefadroxil. It also engages in the distillation of specialty solvents including methonel, acetonitrile, ethyl acetate, and THF, as well as contract manufacturing and custom synthesis business. Its manufacturing operations are based in India, with a corporate office located in Chandigarh, and a new production unit in Haryana where commercial production commenced in 2026. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and export markets. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical API manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in antibiotic therapies, regulatory approvals, and API price fluctuations. 

B. Company Product Lines

• Amoxycillin Trihydrate API 

• Ampicillin Trihydrate API 

• Cloxacillin Sodium API 

• Dicloxacillin Sodium API 

• Flucloxacillin Sodium API 

• Cephalexin API 

• Cefadroxil API 

• Specialty Solvents (methonel, acetonitrile, ethyl acetate, THF) 

• Contract Manufacturing and Custom Synthesis services 

C. Company Revenue Model

• Domestic API Sales 

• Revenue generated through sales of APIs, intermediates, and bulk drugs to pharmaceutical companies and drug manufacturers across India. 

• Export Sales 

• Contribution from international customers in select global markets. 

• Specialty Solvent Sales 

• Income from distillation and sale of specialty solvents for industrial applications. 

• Contract Manufacturing Income 

• Revenue from custom synthesis and contract manufacturing of pharmaceutical ingredients for third-party companies. 

Revenue performance is primarily influenced by demand for generic antibiotics, API price fluctuations, regulatory approvals, and competition from other API manufacturers. 

D. Geographic Presence

• Corporate Office: Chandigarh, India 

• Manufacturing Facilities: Production plants in India, including a new production unit in Haryana (commercial production commenced January 2026) 

• Distribution Network: Domestic distribution across India through pharmaceutical supply channels 

• Export Markets: Products supplied to select international markets 

E. Key Milestones

• 1993: Incorporation of Syschem (India) Limited. 

• 1993: Listing on Bombay Stock Exchange. 

• 2026: Commencement of commercial production at new production unit in Haryana. 

• Recent years: Continued focus on API capacity expansion and solvent distillation. 

F. Industry Perspective

The pharmaceutical API manufacturing industry is capital-intensive and closely linked to demand for generic drugs, regulatory approvals, and healthcare spending. Demand trends are influenced by disease prevalence, generic drug adoption, and insurance penetration. The industry faces fluctuations in raw material (chemical intermediate) prices, regulatory approvals from CDSCO and international agencies, and competitive pricing from global API manufacturers. Drug price control mechanisms and environmental regulations increasingly shape production practices. Companies in this sector must manage regulatory compliance, supply chain logistics, and competition while maintaining efficient manufacturing processes. These factors collectively influence financial performance and investor perception of firms like Syschem (India). 

Syschem (India) Limited Stock Market Presence: Listings and Index Representation 

Syschem (India) Limited is listed on the Bombay Stock Exchange (BSE) under the scrip code 531173. Syschem share price is actively traded on the BSE platform. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Syschem stock price is generally tracked by investors interested in the API and bulk drug pharmaceutical industry. 

Syschem (India) Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap index under the pharmaceutical classification. Syschem share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other API and pharmaceutical manufacturing companies. 

Syschem (India) Limited Stock Performance and Share Price History 

Syschem share price on the BSE reflects its position as an API and bulk drug manufacturer in India. Its performance is qualitatively driven by factors such as production capacity utilization at its new Haryana unit, management of raw material costs including chemical intermediates, growth in contract manufacturing, and the ability to control operational expenses. Investors compare Syschem share price current movement with other API and pharmaceutical companies to assess relative strength. 

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported the stock at various points. Beyond operational and sector influences, corporate actions, such as the commencement of commercial production at the new production unit in Haryana in January 2026, have significantly affected Syschem share price movements by shaping future growth expectations and expanding capacity. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by CDSCO approval cycles and API price competition. 

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by Syschem share price annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger API demand and stable chemical prices, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of drug pricing policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance. 

Syschem share price behaviour mirrors the trading patterns of a small-cap API company within India’s generic pharmaceutical ecosystem. The company’s API portfolio spanning amoxycillin, ampicillin, cloxacillin, dicloxacillin, flucloxacillin, cephalexin, and cefadroxil has shaped its price history. Over the past several years, the stock has experienced periods of sharp gains followed by phases of consolidation. For instance, it delivered positive returns in certain years when demand for antibiotic APIs increased, but recorded negative returns in other years, underperforming the broader small-cap index over one year, three year, and five year horizons. The stock has shown higher volatility compared to the overall market. 

The company’s performance has closely tracked India’s generic drug demand and API price cycles. Positive momentum in Syschem share price appeared when the company announced the commencement of commercial production at its new Haryana unit and reported quarterly results, with profit of 41.7 million rupees in the December quarter. However, periods of high raw material costs and competitive pressure from larger API manufacturers have led to consolidation in Syschem share price. Profitability has shown variability in recent quarters, primarily due to raw material price fluctuations and order book timing. 

Despite industry disruptions, Syschem shares showed resilience during the recovery phase. While the broader pharmaceutical sector faced supply chain challenges, the company’s established API manufacturing capabilities helped the stock recover from fluctuations. The company maintains a workforce of 115 employees and continues to focus on capacity expansion. 

Syschem share price has declined for several recurring reasons. A drop in demand for specific APIs like amoxycillin directly impacts production volumes and leads to selling pressure. Changes in government policy regarding drug price controls or import duties on chemical intermediates can also cause the stock to fall. Moreover, increases in operational costs such as chemical intermediate procurement or energy expenses without matching price increases squeeze margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending raise concerns about API volumes, leading to price declines. Syschem share price is sensitive to regulatory news; if the CDSCO issues warnings or import alerts, it can cause the stock to fall as investors adjust expectations for future growth. Broader market selloffs in small-cap pharmaceutical stocks also pull Syschem share price lower, regardless of the company’s individual performance. Lower capacity utilisation or reduced export orders directly hurts revenue, resulting in a lower valuation. 

Syschem (India) Limited Investor Relevance and Role in Portfolio 

Syschem (India) Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to API manufacturing for penicillin-based antibiotics and specialty solvents. Its inclusion in pharmaceutical indices underscores its importance in India’s generic drug API manufacturing space. The company’s position as a manufacturer of antibiotic APIs with a new production unit in Haryana, together with its contract manufacturing and custom synthesis capabilities, makes it a consideration for long-term allocations. 

Syschem share price is influenced by the company’s ownership structure. Syschem’s equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake, reflecting strong internal control. The public holds the remaining stake. The company’s management includes Managing Director & Executive Director Ranjan Jain, Executive Director Suninder Veer Singh, Independent Non-Executive Chairman Arshdeep Kaur, and Chief Financial Officer Sanjeev Agrawal. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical API manufacturing. 

Beyond fundamentals and ownership, Syschem stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, regulatory approvals, and policy actions affecting drug pricing. The stock is available for trading on the BSE, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in drug price control orders. 

Technical indicators provide additional insight into short-term momentum shifts in Syschem share price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, Syschem share price has a P/E ratio of approximately 31.66 and an EPS of ₹1.48. The company’s debt to equity ratio reflects a moderate use of leverage. Return on equity and return on capital employed are at modest levels, and the company’s book value per share serves as a reference point for valuation. 

Overall, Syschem stock price demonstrates moderate to higher volatility depending on the measurement period, with the stock generally considered to have sensitivity to sector-specific factors such as API price fluctuations, regulatory approvals, and competition in the antibiotic API market. 

Syschem (India) Limited Sectoral Relevance and Peer Positioning 

Syschem (India) Limited sector relevance stems from its three-decade presence in the API manufacturing industry, its position as a manufacturer of amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, and cefadroxil APIs, its specialty solvents distillation business including methonel, acetonitrile, ethyl acetate, and THF, its contract manufacturing and custom synthesis services, its manufacturing facilities including a new production unit in Haryana (commercial production commenced January 2026), its corporate operations based in Chandigarh, and its role as a supplier of penicillin-based antibiotic APIs to generic drug manufacturers, establishing it as a focused small-cap API provider supporting India’s pharmaceutical manufacturing ecosystem. Peer comparisons with API manufacturing companies like Aurobindo Pharma, Granules India, Laurus Labs, and other antibiotic API manufacturers focus on production capacity, product mix, export presence, and value-added product diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API prices, drug price controls, and CDSCO approvals further highlights Syschem positioning within India’s broader API manufacturing market. 

Syschem P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API sales and specialty solvents. Based on available data, the current P/E ratio has shown variation with earnings cycles. The company’s profit after tax improved in recent periods, with profit of 41.7 million rupees in the December quarter. Quarterly performance has shown sequential improvement in certain periods. The company’s net profit margin has shown improvement in recent quarters. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical API industry. 

Alongside valuation, Syschem earnings per share provide insight into its operational performance and income generation from API and solvent sales. Based on available data, the company reported a basic EPS in recent quarters that has shown improvement compared to prior periods. The trailing twelve-month EPS stands at certain levels. Syschem EPS for the last full fiscal year was influenced by input cost pressures and competitive pricing conditions. The company has a standard face value per share. More recent quarterly performance suggests that EPS has shown responsiveness to cost optimization and improved product mix. 

Syschem market cap highlights its position as a small-cap player within India’s API manufacturing sector. Based on recent data, the company’s market capitalization fluctuates within a range of approximately ₹219 crore to ₹248 crore depending on the reporting period. Syschem market cap has moved in line with investor perceptions of the company’s growth potential following the commencement of production at its new Haryana unit. From earlier years through more recent periods, the market cap showed an increasing trend as the company expanded its production capacity, followed by a significant correction. This pattern reflects investor confidence during favourable pharmaceutical cycles, followed by contraction during challenging periods impacted by cheap API imports and rising raw material costs. This decrease mirrors the correction in Syschem share price from its annual high to recent levels. 

Finally, Syschem earnings trajectory demonstrates the impact of its operational execution in a competitive API industry. In recent fiscal years, total income showed growth supported by the core API business. Based on available data, the company’s revenue from operations increased in the most recent quarter compared to the same quarter of the prior year. Total income increased over the same period. Profit after tax improved in certain periods. However, quarterly performance has shown variability across different quarters. The company has faced headwinds from fluctuating chemical intermediate prices, cheap API imports, and increased competitive pressures from larger API manufacturers. However, the company has expanded its production capacity with a new unit in Haryana and expects further growth in the coming periods. These developments illustrate the cyclical nature of the API manufacturing industry and the company’s position within this sector. 

Over time, Syschem market cap has moved in relation to API sector peers. The company’s earnings have followed the pattern typical of API manufacturing businesses, with revenue performance connecting directly to bulk drug demand and raw material cycles. Quarterly earnings have shown variability influenced by raw material costs and export order flow. The earnings per share figure has followed the trajectory of overall profitability. The price-to-earnings multiple has varied over time, reflecting changing investor expectations about demand for antibiotic APIs. When generic drug demand picks up and chemical costs stabilize, the multiple may expand. Conversely, during periods of weak demand or rising raw material costs, the multiple may contract. Comparisons with peer API manufacturing companies help investors understand relative valuation. 

Syschem market cap reflects the company’s position within India’s small-cap API manufacturing space. Over time, the market valuation has tracked investor perception of the company’s ability to scale its antibiotic API production. The company’s expansion with a new production unit in Haryana has shaped expectations around capacity growth. Comparisons with peer API manufacturing companies help investors assess relative scale. These factors collectively determine how Syschem market cap moves in relation to sector peers and broader small-cap pharmaceutical indices. 

Syschem earnings have followed the pattern typical of API manufacturing businesses, with revenue performance connecting directly to bulk drug demand and raw material cycles. Quarterly earnings have shown variability, influenced by raw material costs and order flow. Net profit levels have improved in recent periods from a low base. Operating margins reflect the balance between API realisations and raw material costs. 

Syschem EPS provides insight into per share income generation from the company’s API manufacturing operations. The earnings per share figure has followed the trajectory of overall profitability, with quarterly results showing responsiveness to industrial cycles. Per share earnings have been affected by revenue mix shifts between antibiotic APIs and specialty solvents. Comparing EPS across periods helps market participants assess whether operational improvements translate into per share growth. 

Syschem P/E ratio represents the market’s valuation of the company’s earnings generation capacity within the API manufacturing sector. The multiple has varied over time, reflecting changing investor expectations about growth from new production capacity and contract manufacturing. When API margins improve for amoxycillin and other antibiotics, the multiple may expand. Conversely, during periods of weak demand or increased import competition, the multiple may contract. Comparisons with peer API manufacturing companies help investors understand relative valuation. 

Summary 

Syschem (India) Limited operates as a small-cap API manufacturing company with a three-decade operating history, specializing in amoxycillin, ampicillin, and other penicillin-based antibiotics for the pharmaceutical industry. Syschem share price reflects investor assessment of generic drug demand, API price cycles, and regulatory approvals. The stock trades on the BSE within the small-cap segment. Operational performance depends on API demand and raw material costs, while Syschem stock price movements are observed by market participants tracking the API and generic pharmaceutical sector.